KBC Securities - Koninklijke Ahold Delhaize N.V. (AD) Morning Notes : AD NA

Report

KBC Securities

Hilde Van Boxstael ...

Michiel Declercq
Wim Lewi

Morning Notes : AD NA

: AD NA

05/12/2024 1 EN

Underlying

Koninklijke Ahold Delhaize N.V.

Koninklijke Ahold Delhaize is an international group of supermarket and foodservice operators based in Europe and the U.S. Co. operates supermarkets and convenience stores. In addition, Co. provides online food retailing services. Co. also finances, develops and manages store sites and shopping centers. Ahold Europe comprises Albert Heijn in the Netherlands and Belgium; Etos, Gall & Gall, and albert.nl in the Netherlands; and Albert / Hypernova in the Czech Republic and Slovakia. Ahold USA is organized into four retail divisions: Giant Carlisle, Giant Landover, Stop & Shop New England, and Stop & Shop New York Metro. The Peapod online business is also part of Ahold USA.

See profile

NL0011794037 Euronext Amsterdam Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Michiel Declercq

Wim Lewi

Other Reports on these Companies

ING Financial Markets

Benelux Morning Notes

Ahold Delhaize: Walmart 3Q24/25 results. IBA: Rhodotron contract to equip a sterilization facility in Mexico. NEPI Rockcastle: Sound operational momentum. UCB: Final approval for Bimzelx in the United States

November 20, 2024 November 20, 2024 1 EN

ING Financial Markets

Ahold Delhaize/3Q23 postview: US margin starts to fall/HOLD

We reiterate our HOLD rating and €32 target price on Ahold Delhaize as we continue to carry below consensus estimates for FY24/25F due to required price investments in the United States to reignite volume growth for some store formats. We expect this to allow Ahold Delhaize to meet its HSD Core EPS CAGR target over 2024-28F, with INGF standing c.5% above Visible Alpha consensus on Core EPS 2028F. In the short term, however, we see limited catalysts for the group, except for a potential corporate tax rate cut in the US, which would lead to an increase of only c.4% in our equity value. At our ta...

November 13, 2024 November 13, 2024 1 EN

Fagron FIRST LOOK: Deep-dive into Fagron's warning letter

Following a conference call with management and a readthrough of the warning letter regarding Fagron's Wichita site, our assessment confirms that the issues highlighted in the letter refer mainly to observations that were already known to and being addressed by Fagron since last summer. While the language used by the FDA in the letter is strong, we interpret this in a broader context of the regulator raising the bar on quality standards in the pharmaceutical compounding industry. Three topics were highlighted in the conf call related to product labelling, environmental monitoring and Fagron's ...

December 23, 2024 December 23, 2024 1 EN

Jacob Mekhael ... (+2)

Jacob Mekhael
Thomas Vranken

Sequana Medical FDA approval for alfapump

Sequana receives a nice Christmas present this year as it obtained PMA approval from the FDA for its alfapump system in the treatment of r/r ascites due to liver cirrhosis, ahead of the guided 1Q25 timeline. We see the approval as an important derisking event for the company, which will enable the company to address a market opportunity of $ >2bn (mgmt. estimates) in the US. The commercialisation intends to specifically target 90 liver transplant centres and is expected to launch in 2H25. We note that Sequana's current cash runway extends into 1Q25. With approval in hand, the company could aim...

December 23, 2024 December 23, 2024 1 EN

Hilde Van Boxstael ... (+3)

Hilde Van Boxstael
Thomas Vranken
Wim Lewi

Morning Notes : FAGR BB, SEQUA BB

: FAGR BB, SEQUA BB

December 23, 2024 December 23, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : AD NA

We are a financial services provider for several types of professional clients, each with distinct needs.

Benelux Morning Notes

Ahold Delhaize/3Q23 postview: US margin starts to fall/HOLD

Fagron FIRST LOOK: Deep-dive into Fagron's warning letter

Sequana Medical FDA approval for alfapump

Morning Notes : FAGR BB, SEQUA BB

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe